ArticleEndocrine connections2025
Intratumoural aldosterone and CYP11B2 expression levels among different genotypes of aldosterone producing tumours.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging methods for subtype differentiation in primary aldosteronism.Journal of internal medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism is the most common endocrine cause of hypertension, affecting 5-10% of hypertensive patients. Determining the source of aldosteronism is necessary for correct diagnosis and further molecular analysis. To investigate the relationship between aldosterone synthase (CYP11B2) expression and aldosterone synthesis, we analysed tissue aldosterone and CYP11B2 expression in different genotypes of unilateral PA disease (uPA). Forty-eight tumour samples from patients with confirmed uPA were included. Intratumoural aldosterone was detectable in most uPA cases and correlated with CYP11B2 protein expression (r 2 = 0.48, P < 0.0001). Aldosterone concentrations were significantly higher in tumours with ATP1A1, ATP2B3 and CACNA1D mutations compared to those with KCNJ5 mutations (P = 0.0001). Using CYP11B2 expression and tissue aldosterone, five tumours were reclassified as non-functional nodules. Furthermore, a second active nodule responsible for the aldosteronism, also carrying a driver mutation, was identified in these patients. These findings show that CYP11B2 expression relates to cell concentrations of aldosterone and may be used to clarify the source of aldosterone secretion. Furthermore, the results corroborate genotype differences between uPA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.